Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Pfizer expects seniors with health problems to be first

Pfizer expects seniors with health problems to be first

A healthcare worker gives the Pfizer / BioNTech vaccine to Norman G. Einspruch, an 88-year-old cardiology patient, as part of a COVID-19 adult vaccination plan at Jackson Memorial Hospital in Miami, Florida, USA on December 30, 2020. .

Marco Belo Anadolu Agency Getty Images

High-risk groups such as the elderly and people with concomitant medical conditions are expected to be the first in line to receive booster photos of the Pfizer-BioNTech Covid-1

9 vaccine, the company’s chief research officer said on Tuesday.

The two-dose vaccine has been shown to be about 95% effective against Covid two weeks after the second dose, although researchers who helped develop the shot now say they are beginning to see the strong defenses weaken over time.

Earlier, executives at Pfizer and BioNTech told CNBC that people would likely need a booster or a third dose of Covid-19 within 12 months of full vaccination. They also said people would probably have to take extra pictures each year.

During a call for revenue on Tuesday, Mikael Dolsten, Pfizer’s chief research officer, said it made sense to start with the most vulnerable, such as the elderly and those with chronic illnesses, who make them more vulnerable to serious illness and hospitalization. such as cardiovascular disease or asthma.

“We can’t predict what the CDC and the FDA will do,” he added.

Dolsten’s comment comes after the company announced that sales of its Covid-19 vaccine boosted financial results for the first quarter.

The company now expects year-round sales of $ 26 billion from the vaccine, up from a previous estimate of about $ 15 billion. He expects adjusted pre-tax profit in the high 20% of vaccine revenue.

“Based on what we’ve seen, we believe that continued demand for our Covid-19 vaccine, similar to that of influenza vaccines, is a likely outcome,” Pfizer CEO Albert Burla told investors in the call for profit.

If Americans need booster shots, the U.S. government will likely have to agree with drug manufacturers to provide additional doses and make plans to distribute vaccines.

Last month, Andy Slavitt, senior adviser to President Joe Biden’s response team at Covid, said the White House was preparing for the potential need for injections to tow Covid-19 vaccines. He said the Biden administration was thinking about the need to provide additional doses.

Source link